Annual report pursuant to Section 13 and 15(d)

Acquisition of Pelican Therapeutics (Schedule of Purchase Price of Assets and Liabilities) (Details)

v3.19.1
Acquisition of Pelican Therapeutics (Schedule of Purchase Price of Assets and Liabilities) (Details) - USD ($)
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Aggregate consideration:      
Contingent consideration $ 2,385,000  
Purchase price allocation:      
Goodwill 2,189,338 $ 2,189,338
Pelican Therapeutics, Inc. [Member]      
Aggregate consideration:      
Cash consideration 500,000    
Stock consideration 1,052,000    
Contingent consideration 2,385,000    
Total Consideration 3,937,000    
Purchase price allocation:      
Cash acquired 31,199    
In-process R&D 5,866,000    
Goodwill 2,189,338    
Deferred tax liability (2,111,760)    
Net liabilities assumed (1,102,777)    
Fair value of non-controlling interest (935,000)    
Total purchase price $ 3,937,000